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Table I 
Vander Salm series (all patients) Lemmer series (primary CABG) 
Control EA CA Control Aprotinin 
Chest tube drainage rate (ml/hr) 
Chest tube drainage (ml) 
Mean No. units of RBCs transfused 
35 27 87 41 
839 647 1503 855 
1.35 1.13 2.1 1.1 
RBCs, Red blood cells. 
treated group. In our series, the mean units of red cells 
transfused in all patients (both EACA and control groups) 
with primary operations was only 0.84, a number less than 
that of both the control and aprotinin-treated groups 
receiving a primary CABG in Lemmer's eries. In a study 
of primary CABG operations reported by Daily and 
colleagues, 3 the number of patients receiving transfusions 
was significantly ess in the EACA-treated patients (4.8%) 
than in those in the control group (26.3%). 
Lemmer points out that we did not compare aprotinin 
against EACA. He is correct. We did not intend to do so. 
We only wished to ask whether EACA reduces blood loss 
when compared with a control series not receiving EACA. 
The only comparison of EACA with aprotinin made in 
our paper was of the cost of the two drugs. We did not 
claim that EACA more effectively reduces bleeding than 
does aprotinin, only that it does so less expensively. In 
fact, we are currently engaged in a Bayer-supported study 
of aprotinin to ascertain whether its documented reduc- 
tion of bleeding reduces transfusion costs and other 
intensive care unit costs (such as ventilator support) 
sutficiently to offset the high cost of the drug. 
We are embarrassed to realize that our paper contains 
an egregious numerical error--as Lemmer noticed and we 
did not. In the original manuscript, he cost of aprotinin 
was based on the (correct) volume use of the high-dose 
regimen: 200 ml before institution of cardiopulmonary 
bypass, 200 ml in the heart-lung pump prime, and an 
infusion rate during the operation of 50 ml/hr. When the 
final manuscript was submitted, the aprotinin dose was 
converted from milliliters to kallikrein inactivator units 
(kIU) and a tenfold error was introduced. None of the 
authors noticed the error. The correct doses are 2 × 106 
kIU before cardiopulmonary b pass, 2 × 106 kIU in the 
pump prime, and 0.5 × 106 kIU/hr infusion--not en 
times that dose, as was published. However, since the cost 
calculation was based on the volume dose used, the cost 
calculation of $785 per patient is correct as published, and 
the comparison with the $6.96 per-patient EACA cost 
remains rather striking. We apologize for the error, which, 
fortunately, did not affect the cost calculation in our 
paper. When we use aprotinin, we use the standard 
high-dose regimen as described above and in the package 
insert. 
Although Lemmer is critical of our conclusions, we 
suspect hat we both have nearly identical indications for 
the use of aprotinin. As does he, we use it only in 
operations expected to carry a high bleeding risk. We 
probably differ in that we do not use the drug routinely in 
redo operations because we do not consider those to carry 
a high bleeding risk. 
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Twenty-three-year survival of a bovine pericardial 
bioprosthesis 
To the Editor." 
The letter by Trujillo and colleagues 1 concerning a 
19-year survival of a Hancock I porcine mitral bioprosthe- 
sis (Johnson & Johnson Cardiovascular, King of Prussia, 
Pa.) prompts us to report his 23-year survival of a bovine 
pericardial bioprosthesis in the aortic position. 
A male patient was noted to have a cardiac murmur on 
routine medical examination at the age of 11 years. In 
1972, at the age of 36 years, he was referred for treatment 
because of a 3-year history of dizziness, double vision, and 
progressive dyspnea on moderate xertion. A diagnosis of 
aortic stenosis was made. The patient was not evaluated 
by cardiac catheterization. On October 10, 1972, he 
underwent aortic valve replacement. A heavily calcified 
bicuspid aortic valve was excised and replaced with a 20 
mm standard-profil e Ionescu pericardial xenograft hat 
had been constructed by the surgical team at the Leeds 
General Infirmary. He made an uncomplicated postoper- 
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ative recovery. No anticoagulants or antiplatelet agents 
were administered after the operation. 
The patient returned to work as a nurse. He continued 
to pursue active sporting hobbies and was walking in the 
Austrian Alps in July 1995 and regularly playing badmin- 
ton until April 1996. He was followed up on an annual 
basis in the surgical outpatients' clinic. A routine echocar- 
diogram in March 1996 showed mild stenosis across the 
aortic xenograft with a gradient of 33 mm Hg. One month 
later he was admitted on an emergency basis after an 
episode of severe chest pain. He had become acutely 
breathless and was noted to have a cardiac murmur. 
Clinical examination at this point revealed severe aortic 
regurgitation. This was confirmed by transesophageal 
echocardiography. Coronary angiography revealed addi- 
tional triple-vessel coronary artery disease. 
On April 30, 1996, he underwent a second aortic valve 
replacement and quadruple coronary artery bypass graft- 
ing. At the operation the prosthesis was noted to be 
moderately calcified. A tear extended from the apex of 
one of the stent posts to the base of the leaflet. At the 
patient's request a Carpentier-Edwards bioprosthesis 
(Baxter Healthcare Corp., Edwards Division, Santa Ana, 
Calif.) was used to replace the previous xenograft. He 
made an uncomplicated recovery and was discharged to 
his home on the eleventh postoperative day. 
This particular bioprosthesis was inserted 1 year after 
Mr. Ionescu began constructing and implanting bovine 
pericardial bioprostheses. Thus this represents he longest 
surviving bovine pericardial xenograft inserted at this 
institute. This particular case confirms that the bovine 
pericardium can be a suitable material for the construc- 
tion of cardiac valvular bioprostheses. The large variation 
in rates of structural deterioration suggests that the design 
and the construction of the valve, together with individual 
patient variables, are major determining factors in their 
rates of failure. 2
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